Since the start of the pandemic, analyst forecasts for 2020 product sales have dropped by $4.9 billion for the top 15 companies, EvaluatePharma found. Merck is expected to lose the most sales this year due to the pandemic, with a decrease of about $1.3 billion.
How the total 2020 sales forecasts changed between March and June for the top 15 pharma companies:
- GlaxoSmithKline: +$650 million
- Eli Lilly: +$243 million
- Gilead Sciences: +$77 million
- Takeda: +$56 million
- Johnson & Johnson: -$7 million
- Bristol-Myers Squibb: -$119 million
- Amgen: -$285 million
- AstraZeneca: -$330 million
- Novartis: -$378 million
- AbbVie: -$512 million
- Sanofi: -$592 million
- Roche: -$619 million
- Bayer: -$675 million
- Pfizer: -$1.2 billion
- Merck: -$1.3 billion
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
CVS fined for understaffing, prescription errors in Oklahoma
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
